The Affilin® scaffold technology platform is a unique tool that rapidly generates multiple new drug candidates, satisfying the need for the pharmaceutical industry to fill pipelines. It is based on a strong and undisputed patent estate.
Affilin® therapeutics are based on the small human serum protein, Ubiquitin. They bind targets with high affinity and specificity, have a low immunogenic potential, allow rapid preclinical development cycles and make use of the endogenous Ubiquitin system.
Affilin® therapeutics have competitive advantages over small molecules, antibodies and other scaffold approaches. Based on a unique mechanism of action, selected Affilin® conjugates provide efficacious treatments with low side effects, enabling the development of novel treatments.
Affilin® product developments focus on cancer and inflammation, areas with high market potential and strong medical need. The disease targets are clinically validated but distinct from those commonly used.
